NVS
Novartis AG ADR
NYSE: NVS · HEALTHCARE · DRUG MANUFACTURERS - GENERAL
$147.85
+3.44% today
Updated 2026-04-30
Market cap
$280.79B
P/E ratio
20.32
P/S ratio
4.96x
EPS (TTM)
$7.16
Dividend yield
3.26%
52W range
$102 – $165
Volume
2.1M
Novartis AG ADR (NVS) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
7 of 8
Last 8 quarters
Avg EPS surprise
+1.5%
Last 4 quarters
Revenue YoY growth
-1.6%
Most recent quarter
EPS YoY growth
+2.5%
Most recent quarter
When is the next earnings report?
Reporting date
March 31, 2026
Consensus EPS estimate
$2.07
Fiscal period ending
2026-03-31
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
-1.5%
Last 2 reports
Positive reaction rate
50%
1 of 2 quarters
Largest single-day move
-5.7%
2025-10-28
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-02-04 | $2.03 | +1.5% | $149.86 | $153.95 | +2.7% |
| 2025-10-28 | $2.25 | -2.6% | $129.14 | $121.80 | -5.7% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2026-03-31 | $2.07 | — | — | — | — |
| 2025-12-31 | $2.00 | $2.03 | +1.5% | $13.33B | -1.6% |
| 2025-09-30 | $2.31 | $2.25 | -2.6% | $14.36B | +9.0% |
| 2025-06-30 | $2.37 | $2.42 | +2.1% | $14.84B | +15.3% |
| 2025-03-31 | $2.17 | $2.28 | +5.1% | $13.62B | +12.4% |
| 2024-12-31 | $1.76 | $1.98 | +12.5% | $13.56B | +15.1% |
| 2024-09-30 | $1.93 | $2.06 | +6.7% | $13.17B | +8.9% |
| 2024-06-30 | $1.86 | $1.97 | +5.9% | $12.87B | +9.6% |
| 2024-03-31 | $1.68 | $1.80 | +7.1% | $12.12B | — |
| 2023-12-31 | $1.66 | $1.53 | -7.8% | $11.78B | — |
| 2023-09-30 | $1.74 | $1.74 | +0.0% | $12.09B | — |
| 2023-06-30 | $1.76 | $1.83 | +4.0% | $11.74B | — |
Analyst EPS and revenue estimates for upcoming years
| Period | EPS estimate | Revenue estimate | Revenue growth | Analysts | Confidence |
|---|---|---|---|---|---|
| 2026 (E) | $8.97 | $58.0B | +2.3% | 28 | high |
| 2027 (E) | $9.83 | $61.0B | +5.3% | 28 | high |
| 2028 (E) | $10.45 | $64.4B | +5.5% | 28 | medium |
| 2029 (E) | $11.15 | $68.1B | +5.7% | 28 | medium |
| 2030 (E) | $11.90 | $72.0B | +5.7% | 28 | medium |
Frequently asked questions
When does Novartis AG ADR report next earnings?
Novartis AG ADR (NVS) is scheduled to report earnings on March 31, 2026. The consensus EPS estimate is $2.07.
Has Novartis AG ADR beaten earnings estimates?
Novartis AG ADR has beaten Wall Street EPS estimates in 7 of its last 8 quarterly reports, with an average EPS surprise of +1.5% over the last 4 quarters.
How does NVS stock react to earnings?
NVS stock has moved an average of -1.5% in the trading day following earnings over its last 2 reports, with positive reactions in 50% of those quarters.
What is Novartis AG ADR's revenue growth rate?
Novartis AG ADR reported year-over-year revenue growth of -1.6% in its most recent quarter, with EPS growing +2.5% year-over-year.
What is the expected EPS for NVS in 2026?
Analysts expect Novartis AG ADR to report EPS of $8.97 for fiscal year 2026, on revenue of $58.0B, based on estimates from 28 analysts.